Ophthalmology

Xiidra (lifitegrast) in dry eye disease: what the OPUS trials actually showed

Lifitegrast blocks LFA-1 binding to ICAM-1, interrupting T-cell adhesion before the inflammatory cascade begins. The OPUS programme is more nuanced than it is usually described: no single trial met both its sign and its symptom endpoint, and reading all thr...

Noninvasive bioelectric therapy for dry AMD enters pivotal trial

A noninvasive bioelectric therapy for dry age-related macular degeneration (AMD) has begun a pivotal study. The device aims to address the unmet need for effective treatments in this patient population.

Dry eye: Why current treatments fall short, and what's next

A novel molecule derived from extremophile bacteria shows promise in improving symptoms and signs of dry eye disease, addressing a significant unmet need.

Missing neuropathic corneal pain means prolonged patient suffering

Neuropathic corneal pain presents a significant challenge, often persisting despite conventional treatments and requiring a multi-modal approach.

Ocular surface disease: The overlooked comorbidity complicating glaucoma management

Ocular surface disease is an essential, often missed, component of glaucoma care, impacting treatment adherence and quality of life.

Eye Specialists Question Value of Pricey Cataract Lenses

European ophthalmologists are raising concerns about the increasing use and cost of premium intraocular lenses in cataract surgery, citing limited evidence of superior patient outcomes.

Surgical Start Time Does Not Impact Cataract Complication Rates

New research indicates that the time of day cataract surgery begins has no bearing on postoperative complication rates, challenging long-held assumptions.

Presbyopia Treatment Needs Personalisation, Not One-Size-Fits-All

Patient-specific factors dictate satisfaction with presbyopia-correcting intraocular lenses, with preoperative simulation tools emerging to tailor treatment.

Urcosimod Enters Phase 3 for Neuropathic Corneal Pain

Urcosimod, an investigational therapy, will advance to Phase 3 trials to evaluate its efficacy in treating neuropathic corneal pain, addressing a significant unmet clinical need.